TGFB1 and colorectal carcinoma: These findings directly contradict our previously published work [4] showing low activin and low TGF-β are associated with improved outcomes in CRC; however, this data set provides a more robust cohort across multiple stages of CRC, providing a more reliable insight into the role for these molecules in the TME and their influence on survival.